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A 32 kDa phospholipase 4 inhibitory protein was isolated from pig thyroid gland after calcium precipitation and fast 
protein liquid anion-exchange chromatography. SDS-polyacrylamide gel electrophoresis revealed the purity of the pro- 
tein. The protein activity was assessed by the inhibition of pancreatic phospholipase A2 on PH]oleic acid-labelled Escher- 
ichia coli membranes as substrate and on the prostaglandin E2 production of cultured thyroid cells. The amino acid com- 
position and the isoelectric point were quite similar to those of endonexin previously described in other tissues or cells. 
The cross-reactivity of a polyclonal antibody against a 32 kDa lipocortin from human peripheral blood mononuclear 
cells with our thyroidal 32 kDa protein confirmed its lipocortin nature. Before the purification by fast protein liquid chro- 
matography, the Ca2+ pellet contained lipocortin I (35 kDa and its core protein 33 kDa) identified by its cross-reactivity 
with a polyclonal antibody. 
Lipocortin; Endonexin; Phospholipase 4; Thyroid 
1. INTRODUCTION 
Lipocortins have been initially described as anti- 
inflammatory proteins acting through an in- 
hibitory effect on phospholipase A2 (PLA2) [l-5]. 
They have been described in several tissues and 
cells: rat macrophages [2], rabbit neutrophils [3], 
rat renomedullary interstitital cells [5], human 
fibroblasts [6], mouse and bovine thymus [7], 
human monocytes [8]. Since these previous works, 
lipocortins have been cloned and sequenced [9- 1 l] 
and related to a group of calcium- and 
phospholipid-binding proteins named calpactins I 
and II, calelectrin, endonexin, calcimedin, 
chromobindin [ 12-201. All these proteins 
presented a 17 amino acid sequence homology [ 161 
also shown in ras gene proteins [21]. Lipocortins 
exist in two types I and II identical to calpactin II 
and I, respectively [11,221, and are phosphorylated 
by tyrosine kinases [ 12,23-251 or by protein kinase 
C [4,26,27]. Moreover, their anti-PLAZ activity is 
regulated by phosphorylation [4,25,26]. 
In previous works, we described the important 
role played in the thyroid tissue by the 
phospholipase A2 activity and its regulation by 
thyrotropin [28-3 11. The present study provides 
the evidence that a 32 kDa phospholipase AZ in- 
hibitory protein exists in thyroid tissue and that it 
has an inhibitory effect on thyroid cellular 
phospholipase AZ. 
Correspondence address: F. Antonicelli, Laboratoire de 
Biochimie, UFR Sciences, BP 347, 51062 Reims Cedex, France 2. MATERIALS AND METHODS 
Abbreviations: PLAz, phospholipase AZ; PMSF, phenyl- [‘HJOleic acid (4.2 Ci/mmol) was purchased from Amer- 
methylsulfonyl fluoride; Hepes, N-2_hydroxyethylpiperazine- sham, France; porcine pancreatic PLAa from Boehringer, 
N’-2-ethanesulfonic acid Mannheim; fatty acid free bovine serum albumin from Sigma. 
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2.1. Purification of PLAz inhibitory profeins 
2.1.1. Ca2+ purification 
50 g pig thyroid tissue was hashed after elimination of the 
connective and fat tissues and homogenized using a Polytron 
with 250 ml of a pH 7.6 buffer containing 10 mM Hepes, 
100 mM NaCl, 5 mM EDTA, 2OOpM PMSF and 1000 U/ml 
aprotinin. 
The homogenate was sonicated 3 x 10 s at 4°C and centri- 
fuged at 20000 x g for 30 min (Sorvall RC2 superspeed centri- 
fuge, DuPont Instruments). 6 mM of CaClz was added to the 
supernatant and left for 30 min at 4°C. After centrifugation at 
39000 x g for 30 min, the pellet was washed with a pH 7.4 buf- 
fer containing 10 mM Hepes, 150 mM NaCI, 1 mM CaClz and 
centrifuged again at 39000 x g for 30 min. The pellet was 
resuspended in 13 ml of 10 mM Hepes, 10 mM EGTA, 2OOpM 
PMSF and 1000 U/ml aprotinin, pH 7.4, buffered solution. 
After centrifugation at 100000 x g for 30 min (Beckman L265B 
Ultra-centrifuge) the supernatant was used for further 
purification. 
2.1.2. Fast protein liquid chromatography 
The purification by fast protein liquid chromatography 
(Pharmacia, Uppsala, Sweden) was carried out as described by 
Rothhut et al. [8] on a strong anion-exchange resin mono Q HR 
5/5 at a flow rate of 1 ml/min except that the initial elution buf- 
fer was 100 mM Tris-HCl, pH 8, containing 1 mM PMSF. The 
injected volume was 200 ~1 (300 pg protein) and the proteins 
were eluted with a NaCl gradient. 
2.1.3. SDS-polyacrylamide gel electrophoresis 
Gradient-SDS (5-15% acrylamide) gels were run using BRL 
(Bethesda Research Laboratories) apparatus or (lo-15% 
acrylamide) gels when the PHAST-system was used. Proteins 
were visualized by Coomassie blue or by silver staining. 
2.1.4. Isoelectric focusing 
Isoelectric focusing was performed with different pH gra- 
dients using the PHAST-system. 
2.2. Antibody recognition 
Different fractions were analyzed by Western blot analysis 
described by Towbin et al. [32] and modified by Rothhut et al. 
WI. 
2.3. Phospholipase (PLAz) inhibifory properties 
The porcine pancreatic PLAz inhibitory assay was performed 
as described by Rothhut et al. [33]. Prostaglandin Ez biosyn- 
thesis was assessed on cultured pig thyroid cells. 
Pig thyroid cells were cultured as previously described [34]. 
After a 4 day culture, cells were washed by 200 x g centrifuga- 
tion with Earle Hepes, pH 7.4, buffered solution and 
resuspended in an RPM1 solution in the presence or absence of 
PLAz inhibitory proteins; at various times, the prostaglandin 
Ez content of the incubation medium was determined with the 
Institut Pasteur kit. 
2.4. Amino acid analysis 
Amino acid composition analysis was performed on 200 yg 
of the 32 kDa protein on a Beckman analyser (Muhichrom 
model B4255) using a Wl (56 x 0.9 cm) column resin Beckman 
as described by Spackman et al. [35]. Values were expressed as 
mol% k SD. 
2.5. Profein measurement 
Proteins were measured as described by Lowry et al. [36]. 
3. RESULTS 
3.1. Purification of a 32 kDa protein from pig 
thyroid gland 
In the chromatographic onditions described in 
section 2, the elution profile on Mono Q of the 
proteins is presented in fig.1. The single peak 
eluted at 150 mM NaCl has an apparent molecular 
mass of 32 kDa (fig.2, lane C). Before the Mono 
Q purification, the 32 kDa protein was the major 
protein of the extract but several other proteins 
were present (fig.2, lane B). Using isoelectric 
focusing, the 32 kDa protein has an isoelectric 
point of 4.85-4.90 (not shown). 
3.2. PLA2 inhibitory properties 
When tested with 0.1 pg porcine PLAz on the E. 
cofi-labelled substrate, 14 pg of the crude extract, 
before the Mono Q purification, gave a 50% in- 
hibition (fig.3, left) and 5.8 pg of the purified 
32 kDa protein gave a 50% inhibition (fig.3, 
right). In a previous study [28], we demonstrated 
that in pig thyroid, the prostaglandin Ez biosyn- 
thesis was closely related to the cellular PLA2 ac- 
tivity. So, to test the cellular PLA2 activity we 
measured the prostaglandin E2 biosynthesis of 
cultured pig thyroid cells in the presence or absence 
of the 32 kDa protein. 3.75 ,ug of the 32 kDa pro- 
tein decreased the prostaglandin E2 biosynthesis of 
thyroid cells by 35% (P < 0.01) in a five hour in- 
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Fig.]. Chromatographic profile of the Cal+ precipitated 
proteins on Mono Q. The sample was applied to the column in 
a pH 8 buffered 0.1 M Tris-HCI solution and the proteins were 
eluted with a NaCl gradient and detected by absorbance at 
280 nm. 
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Fig.2. SDS-PAGE of protein fractions at different purification 
steps. Samples of protein fractions were analyzed by SDS- 
PAGE (5-15% gradient acrylamide gels) before (lane b) and 
after (lane c) the Mono Q purification and visualized by 
Coomassie blue. Arrows on the left indicate the molecular mass 
markers (kDa), phosphorylase b (94); bovine serum albumin 
(67); ovalbumin (43); carbonic anhydrase (30); trypsin inhibitor 
(20) and lactalbumin (14), shown in lanes a. On the right, the 
relative molecular mass of the purified protein is indicated. 
cubation. (The prostaglandin E2 content of control 
thyroid cells was 115 + 5 nmol for 6 x lo5 cells.) 
3.3. Recognition by antibodies 
Immunoreactive proteins were detected by 
Western blotting (fig.4). The polyclonal antibody 
raised against a 32 kDa lipocortin from human 
peripheral blood mononuclear cells (fig.4, left) 
recognized the 32 kDa component of the purified 
fraction (lane 2) and of the calcium precipitate 
fraction (lane 1). Moreover an anti-serum against 
recombinant lipocortin I antibody (fig.4, right) 
recognized the 33 kDa and 35 kDa proteins in the 
calcium-precipitate fractions (lane 1). These pro- 
teins were absent in the purified Mono Q fraction 
(lane 2). 
3.4. Amino acid composition 
Table 1 shows the amino acid analysis of the 
32 kDa protein. 
4. DISCUSSION 
In this paper we describe the purification and the 
characterization of a 32 kDa PLAz inhibitory pro- 
tein from pig thyroid gland. This protein belongs 
to a group of calcium-precipitable proteins 
described previously in many tissues and cells 
[2,3,5-g]. Biochemical studies (molecular relative 
mass, isoelectric point and amino acid composi- 
tion) show that the 32 kDa thyroid protein shares 
common properties with endonexin [20,37]. Never- 
theless we could demonstrate that this protein was 
recognized by a polyclonal antibody raised against 
a lipocortin indicating that this 32 kDa thyroid 
protein belongs to the lipocortin family. The pro- 
tein inhibits the pancreatic porcine PLA2 activity 
and the in vivo cellular thyroid PLAz activity. 
These results indicate that the cellular PLAz activi- 
ty was accessible from the outside of the cells or 
that the protein interacted with the membrane 
phospholipids leading to an inhibition of the 
Table 1 
Amino acid composition of the 32 kDa protein 
Amino acid Thyroid 32 kDa Monocyte lipocortin 
(mot%) (mol%) 
Asp 10.9 rf- 0.7 9.9 * 1.0 
Thr 6.9 + 0.5 6.0 + 0.3 
Ser 6.6 +- 0.1 8.3 + 1.6 
Glu 12.8 + 0.5 13.8 * 0.9 
Pro 1.1 + 0.5 2.2 * 0.2 
G1Y 7.7 i- 0.3 9.3 + 1.2 
Ala 8.1 -c 0.3 8.2 + 0.5 
Val 4.3 * 0.2 4.0 * 0.2 
Met 3.1 * 0.7 1.2 f 0.6 
Isoleu 5.5 t- 0.3 4.5 + 0.1 
Leu 13.2 t- 0.2 10.7 + 0.9 
Tyr 2.3 + 1.8 3.8 + 0.6 
Phe 3.9 f 0.1 4.0 + 0.4 
LYS 7.0 + 0.3 7.6 + 1.1 
His 1.1 * 0.1 1.5 + 0.4 
Arg 6.1 ? 0.9 5.7 + 0.7 
Values are expressed as mol% -t SD 
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Fig.3. Dose-response curve of porcine pancreatic PLAz inhibition. Different concentrations of the purified proteins were incubated 
with 0.1 pg of porcine pancreatic PLA2 using labelled E. coli as substrate. Results were expressed in % of PLA2 activity. Left, proteins 
before the Mono Q purification; right, the 32 kDa protein. 
t 2 
1” 
#--a4 
a-68 
Ant1 LCI 
4 45 
Fig.4. Western blot analysis of the proteins. (Left) Cross- 
reactivity with the 32 kDa lipocortin antibody. Lane 1, proteins 
before the Mono Q purification; lane 2, the purified 32 kDa 
protein. (Right) Cross-reactivity with the lipocortin I antibody. 
Lane 1, proteins before the Mono Q puyification; lane 2, the 
purified 32 kDa protein. The arrowheads on the right indicate 
the molecular mass markers (kDa). The arrowheads on the left 
indicate the relative molecular mass of the immunoreactive 
proteins. 
cellular enzyme previously described in other 
tissues and cells [38,39]. Moreover, before the 
purification on the Mono Q HR 5/5 column, 
Western blot analysis revealed in the Ca*+ pellet 
proteins the presence of lipocortin I. The 35 kDa 
protein and its core protein of 33 kDa were 
detected. The pig thyroid gland contains proteins 
of the lipocortin family able to bind calcium and to 
inhibit PLA2. In previous works [28-311 we 
described the important role played in the thyroid 
by the PLAz activity, arachidonate and 
arachidonate metabolites. The PLA2 activity of 
thyroid tissue and cells was under TSH regulation 
[28-3 11. The biosynthesis and the phosphorylation 
of thyroidal lipocortins under chronic or acute 
treatment of cultured pig thyroid cells will be 
described in another paper. 
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